<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3" xml:lang="ru">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">research-focus</journal-id>
      <journal-title-group>
        <journal-title>Research Focus International Scientific Journal</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Research Focus</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub" publication-format="electronic">2181-3833</issn>
      <publisher>
        <publisher-name>Ilm-fan va innovatsiyalar akademiyasi</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.66073/researchfocus.v4i4.1594</article-id>
      <article-id pub-id-type="other" assigning-authority="relibrary.uz">REL-A-012925</article-id>
      <article-categories>
        <subj-group subj-group-type="oak">
          <subject>14.00.00</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="ru">ВИНКРИСТИНОВАЯ НЕЙРОПАТИЯ</article-title>
        <trans-title-group xml:lang="en">
          <trans-title>VINCRISTINE-INDUCED NEUROPATHY</trans-title>
        </trans-title-group>
        <trans-title-group xml:lang="uz">
          <trans-title>VINKRISTIN NEYROPATIYASI</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group content-type="author">
        <contrib contrib-type="author">
          <string-name>Гулямова Дурдона Насриддиновна</string-name>
          <aff>Ташкентский институт усовершенствования врачей, кафедра детской неврологии</aff>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Абдурахмонова Нигора</string-name>
          <aff>Центр детской гематологии, онкологии и клинической иммунологии</aff>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Матякубова Хонзода Бектурдиевна</string-name>
        </contrib>
      </contrib-group>
      <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2025-05-05">
        <day>05</day>
        <month>05</month>
        <year>2025</year>
      </pub-date>
      <pub-date date-type="collection">
        <year>2025</year>
      </pub-date>
      <volume>4</volume>
      <issue>4</issue>
      <fpage>278</fpage>
      <lpage>280</lpage>
      <permissions>
        <license xlink:href="https://creativecommons.org/licenses/by/4.0">
          <ali:license_ref>https://creativecommons.org/licenses/by/4.0</ali:license_ref>
          <license-p>Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="https://relibrary.uz/REL-A-012925/"/>
      <abstract xml:lang="ru">
        <p>Винкристиновая нейропатия представляет собой одно из наиболее распространённых и значимых осложнений химиотерапии с применением винкристина. Она проявляется преимущественно в виде периферических сенсорных и моторных нарушений, что существенно влияет на качество жизни пациентов и может ограничивать продолжение лечения. В статье рассмотрены клинические проявления, патогенетические механизмы, факторы риска, методы диагностики и подходы к профилактике и лечению винкристиновой нейропатии. Отмечается необходимость дальнейших исследований, направленных на разработку эффективных нейропротективных стратегий и улучшение ведения пациентов, получающих терапию винкристином.</p>
      </abstract>
      <trans-abstract xml:lang="en">
        <p>Vincristine neuropathy is one of the most common and significant complications of chemotherapy involving vincristine. It manifests itself predominantly in the form of peripheral sensory and motor disorders, which substantially affects the quality of life of patients and may limit the continuation of treatment. The article considers the clinical manifestations, pathogenetic mechanisms, risk factors, diagnostic methods and approaches to the prevention and treatment of vincristine neuropathy. The need for further research aimed at the development of effective neuroprotective strategies and the improvement of the management of patients receiving vincristine therapy is noted.</p>
      </trans-abstract>
      <trans-abstract xml:lang="uz">
        <p>Vinkristin neyropatiyasi vinkristin qo‘llaniladigan kimyoterapiyaning eng keng tarqalgan va eng muhim asoratlaridan biridir. U asosan periferik sensor va motor buzilishlar ko‘rinishida namoyon bo‘lib, bemorlarning hayot sifatiga sezilarli ta‘sir ko‘rsatadi va davolashni davom ettirishni cheklashi mumkin. Maqolada vinkristin neyropatiyasining klinik ko‘rinishlari, patogenetik mexanizmlari, xavf omillari, tashxislash usullari hamda profilaktika va davolash yondashuvlari ko‘rib chiqilgan. Samarali neyroprotektiv strategiyalarni ishlab chiqish va vinkristin bilan davolanayotgan bemorlarni olib borishni yaxshilashga qaratilgan keyingi tadqiqotlar zarurligi qayd etilgan.</p>
      </trans-abstract>
      <kwd-group xml:lang="ru">
        <kwd>винкристиновая нейропатия</kwd>
        <kwd>химиотерапия</kwd>
        <kwd>нейротоксичность</kwd>
        <kwd>сенсорная полинейропатия</kwd>
        <kwd>побочные эффекты</kwd>
        <kwd>онкология</kwd>
        <kwd>неврологический контроль</kwd>
      </kwd-group>
      <kwd-group xml:lang="en">
        <kwd>vincristine neuropathy</kwd>
        <kwd>chemotherapy</kwd>
        <kwd>neurotoxicity</kwd>
        <kwd>sensory polyneuropathy</kwd>
        <kwd>side effects</kwd>
        <kwd>oncology</kwd>
        <kwd>neurological monitoring</kwd>
      </kwd-group>
      <kwd-group xml:lang="uz">
        <kwd>vinkristin neyropatiyasi</kwd>
        <kwd>kimyoterapiya</kwd>
        <kwd>neyrotoksiklik</kwd>
        <kwd>sensor polineyropatiya</kwd>
        <kwd>nojo‘ya ta‘sirlar</kwd>
        <kwd>onkologiya</kwd>
        <kwd>nevrologik nazorat</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <back>
    <ref-list>
      <ref id="r1">
        <label>1</label>
        <mixed-citation>Verstappen, C. C. P., Heimans, J. J., Hoekman, K., Postma, T. J. (2003). Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs, 63(15), 1549–1563. <pub-id pub-id-type="doi">10.2165/00003495-200363150-00003</pub-id></mixed-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <mixed-citation>Cavaletti, G., Marmiroli, P. (2010). Chemotherapy-induced peripheral neurotoxicity. Current Opinion in Neurology, 23(5), 566–575.</mixed-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <mixed-citation>Gomber, S., Dewan, P., Chhonker, D. (2010). Vincristine induced neurotoxicity: Diagnosis and management. Indian Journal of Pediatrics, 77(6), 643–646. <pub-id pub-id-type="doi">10.1007/s12098-009-0254-3</pub-id></mixed-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <mixed-citation>Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S. Y., Friedlander, M. L., Kiernan, M. C. (2013). Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA: A Cancer Journal for Clinicians, 63(6), 419–437. <pub-id pub-id-type="doi">10.3322/caac.21204</pub-id></mixed-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <mixed-citation>Verstappen, C. C. P., Postma, T. J., Hoekman, K., Heimans, J. J. (2005). Peripheral neuropathy due to chemotherapy: A review on the pathophysiology and therapeutic options. European Journal of Cancer, 41(3), 437–445.</mixed-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <mixed-citation>Starobova, H., Vetter, I. (2017). Pathophysiology of chemotherapy-induced peripheral neuropathy. Frontiers in Molecular Neuroscience, 10, 174. <pub-id pub-id-type="doi">10.3389/fnmol.2017.00174</pub-id></mixed-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <mixed-citation>Windebank, A. J., Grisold, W. (2008). Chemotherapy-induced neuropathy. Journal of the Peripheral Nervous System, 13(1), 27–46. <pub-id pub-id-type="doi">10.1111/j.1529-8027.2008.00156.x</pub-id></mixed-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <mixed-citation>Grisold, W., Cavaletti, G., Windebank, A. J. (2012). Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-Oncology, 14(suppl_4), iv45–iv54. <pub-id pub-id-type="doi">10.1093/neuonc/nos203</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
